Raw Materials for STI Diagnostic Development
Accelerate assay development with validated immunoassay and molecular reagents designed for clinical reliability and scalable manufacturing.
Meridian Life Science partners with diagnostic developers to deliver the critical raw materials needed to build accurate, reproducible STI assays, from high-throughput laboratory systems to rapid point-of-care (POC) platforms.
Build Reliable Sexually Transmitted Infection Assays with Confidence
Accurate, early detection of sexually transmitted infections is critical for effective treatment and prevention of
further transmission. Diagnostic developers need raw materials that perform consistently across diverse sample
types in real-world clinical settings.
Meridian Life Science enables STI diagnostic development with:
- Well-characterized antibodies and antigens
- A broad portfolio of interference blockers
- Robust molecular reagents for sensitive nucleic acid detection
- Scalable solutions to support development, validation and commercialization
Our solutions enable developers to deliver timely, accurate, and reproducible STI diagnostics across diverse testing platforms and clinical workflows.
Clinically Significant STIs We Support
Syphilis
Resurgent syphilis rates highlight the need for sensitive, reliable serological testing to support early diagnosis and effective disease monitoring.
Meridian offers a broad range of sensitive antibody and antigen pairs for syphilis, including an innovative T. pallidum P17 + P45 chimeric recombinant antigen pair for lateral flow tests. Additionally, our range of inhibitor-tolerant molecular master mixes and enzymes for qPCR and LAMP amplification allow direct detection from clinical samples, simplifying the workflow for point-of-case assays.
CT/NG
Rising Chlamydia and Gonorrhea prevalence underscores the need for accessible, high-quality molecular screening.
Meridian enables CT/NG testing with qPCR master mixes for rapid, multiplex detection and minimal processing. Our portfolio includes C. trachomatis MOMP/LPS and N. gonorrhoeae Opa/LOS reagents, ensuring reliable, reproducible assays. Together, these solutions support expanded testing, co-infection detection, and AMR surveillance.
HBV
The WHO aims to close the global gap in HBV diagnosis and reduce new infections by 90% by 2030.
Meridian offers high-performing HBV antigens and antibodies for HBsAg, anti-HBc, or antiHBs tests, along with molecular master mixes and enzymes for viral load, genotyping, or mutational analysis.
HSV
Effective diagnostics and disease monitoring are critical to lowering the risk of spreading HSV.
Meridian has high-performing native and recombinant antigens to HSV-1 and HSV-2 that are ideal for serologic HSV IgG type-specific testing. In addition, our inhibitor-tolerant LAMP and qPCR mixes are highly suited to direct detection and differentiation of HSV-1 and HSV-2 DNA from lesion specimens.
HPV
The WHO aims to achieve a 70% HPV screening target by 2030 to reduce cervical cancer.
Meridian offers the complete solution to HPV testing, including antibodies and antigens to the high-risk strains HPV 16 & 18 for immunoassays, and innovative qPCR master mixes for molecular testing including a Lyo-Ready Genotyping Direct qPCR Urine Mix is ideal for developing self-collection, PCR-based HPV-type tests.
HIV
The WHO and leading global health organizations are working to end the HIV epidemic by 2030.
Meridian’s portfolio of immunoassay HIV reagents includes antigens and sensitive antibody pairs to HIV-p24, HIV-1 gp41 and HIV-2 gp36 for rapid lateral flow assays. In addition, Meridian’s inhibitor-tolerant qPCR and LAMP molecular master mixes are lyophilization capable, ideal for developing ambient-temperature stable assays, and available in specimen-specific formulations for saliva, urine, and blood.
Key Testing Techniques
ELISA/CLIA
Detects antibodies or antigens for specific STIs, supporting high-throughput clinical screening and monitoring.
Lateral Flow
Enable rapid, point-of-care detection of select STIs with easy visual readouts.
PCR
Highly sensitive and specific detection of certain STIs, even in low-abundance samples.
Isothermal Amplification
Offers rapid nucleic acid detection without thermocycling, ideal for decentralized or nearpatient STI testing.
Catalogs & Brochures
FAQs
Do you manufacture diagnostic test kits?
What types of STI assays do your materials support?
Do you offer both immunoassay and molecular reagents?
Can your molecular reagents support direct-from-sample workflows?
Do you provide technical support for assay development?
Are your products manufactured under a quality system?
Can your materials be used in regulated IVD assays?
What makes Meridian different from other reagent suppliers?
Do you offer recombinant or animal-origin-free options?
Discover more in our new STI e-Book
- The evolution of STI testing from early assays to next-generation molecular and immunoassay platforms
- How laboratory, point-of-care, at-home, and self-collection models are improving access, privacy and patient engagement
- Key technology trends, including multiplexing, ambient-stable reagents, and digital connectivity
- Real-world insights from a case study highlighting 40 years of innovation in HIV diagnostics
Together, these advances are breaking down barriers to testing, enabling earlier detection, supporting public health initiatives and improving sexual health outcomes globally.
Download the eBook to discover how modern STI diagnostics are shaping the future of accessible, patient-centered care.